Latin American Federation of the Pharmaceutical Industry

We work for patients and for more sustainable health ecosystems in Latin America and the Caribbean

ABOUT US

We are the Latin American Federation of the Pharmaceutical Industry

We brought together Local Associations and Research and Development Pharmaceutical Companies from Latin America and the Caribbean. We work to promote scientific research and patient welfare, innovating for regional health.

Together we promote access to innovation, the recognition of the value of intellectual property, and the search for bold solutions that allow us to move towards better health systems for all Latin Americans.

WORK AREAS

Our work contributes to creating solutions to major global and regional health challenges

iconos_fifarma-04 3-2
Innovation Ecosystems

iconos_fifarma-04 3-1
Health as Investment

iconos_fifarma-04 3
Access to Innovative Medicines

iconos_fifarma-04 3-3
Support to Regulatory Systems

STATISTICS

The pharmaceutical industry contributes to economic and social development and the generation of employment, health, and prosperity in our region

FIFARMA W.A.I.T. Indicator 2024

Los pacientes latinoamericanos deben esperar en promedio 4.7 años para acceder a tratamientos innovadores o de última generación Un medicamento aprobado por la agencia regulatoria de los Estados Unidos (FDA) en octubre de 2024, solo estará disponible al público en los sistemas de salud latinoamericanos en agosto de 2029 (en promedio). 9 de octubre de 2024. FIFARMA lanzó...

DALL·E 2024-09-24 09.55.45 - A realistic photograph showing a healthcare professional, dressed in a white coat with a stethoscope around their neck, holding the hands of a patient

News

Acceso
Latin American patients must wait an average of 4.7 years to access innovative or cutting-edge treatments

Un medicamento aprobado por la agencia regulatoria de los Estados Unidos (FDA) en octubre de 2024, solo estará disponible al público en los sistemas de salud...

Reliance
New Reliance Regulatory Processes in the United Kingdom: Introducing the International Recognition Procedure (IRP)

Desde el comienzo de 2024, el Reino Unido ha cambiado la forma en que aprueba los medicamentos con algo llamado Procedimiento de Reconocimiento Internacional (IRP). Este...

Network

We are industry leaders

The FIFARMA team works closely with industry executives, national and regulatory authorities in the region, and multilateral organizations. Get the opinion of our leaders.

Yaneth Giha
Executive Director
Sarah Aiosa
MSD – SENIOR VICE PRESIDENT AND PRESIDENT FOR LATIN AMERICA
Flavio Devoto
ABBVIE - VICE PRESIDENT FOR LATAM
Mariela Formas
CIF – Executive Vice President
PERSPECTIVES
One of our core purposes is to work for better health systems in the region. The challenge is to, in addition to thinking and creating jointly, put into action what we imagine, for the good of health and patients.
YANETH GIHA
FIFARMA - EXECUTIVE DIRECTOR
PERSPECTIVES
It is my wish that from FIFARMA we build on the concept of health as an investment for current and future generations, while driving our goal of promoting collaborative work to produce great positive impact in the countries of the region.
GABRIELA PITTIS
TAKEDA - PRESIDENT FOR SOUTHERN CONE, ANDEAN REGION, MEXICO, AND CAC
PERSPECTIVES
América Latina es un área muy importante para la investigación clínica, con una rica diversidad de poblaciones que pueden contribuir con conocimientos valiosos y aumentar la precisión de los resultados
FLAVIO DEVOTO
VICEPRESIDENTE PARA AMÉRICA LATINA DE ABBVIE.
PERSPECTIVES
Trabajamos en estrecha colaboración con los gobiernos para construir estrategias efectivas de salud pública
SARAH AIOSA
PRESIDENTA DE MERCK PARA AMÉRICA LATINA
MEMBERS

Local associations

Logos_Fifarma-01
Logos_Fifarma-02
Logos_Fifarma-03
Logos_Fifarma-04
Logos_Fifarma-05
Logos_Fifarma-06
Logos_Fifarma-07
Logo 70 anŞos_BW
Logos_Fifarma-10
Logos_Fifarma-09
Logos_Fifarma-11

Companies

Logos_Fifarma-12
Logos_Fifarma-13
Logos_Fifarma-14
Logos_Fifarma-15
Logos_Fifarma-17
Logos_Fifarma-18
Chiesi-logoB&W 02
gilead-create-possible-svg-01
johnson-johnson-logo
Eli_Lilly_and_Company-B&W
Logos_Fifarma-20
Logos_Fifarma-21
novartis-logo-01
NVO_BIG
Pfizer_Logo_Black_RGB
Logos_Fifarma-23
Logos_Fifarma-31
Logos_Fifarma-24

Partners

Logos_Fifarma-25
Logos_Fifarma-26
Logos_Fifarma-27
Logos_Fifarma-28
Logos_Fifarma-29
LATEST NEWS AND BLOG

Stay up to date with our latest publications

DALL·E 2024-10-15 11.58.10 - A visually engaging image depicting the issue of counterfeit medicines in Latin America. The image features a close-up of medicine packaging with obvi

El Impacto de los Medicamentos Falsificados en América Latina

Diverse group of people sitting together in hospital waiting room
Latin American patients must wait an average of 4.7 years to access innovative or cutting-edge treatments
1727902526469
61° Consejo Directivo de la OPS: Acceso y uso racional de medicamentos estratégicos y de alto costo y otras tecnologías de salud
Firefly Paciente acostado en una cama de hospital, con equipo médico alrededor. Un médico atento est
América Latina debe elevar su inversión en salud, revela nuevo estudio de la Universidad de São Paulo